Dave Allen is SVP of Medicine Design, GSK Research and Development, which includes departments accountable for the design and delivery of small molecule and biopharmaceutical candidate medicines in partnership with the research pipeline owners. The function provides expertise and has accountability for screening, protein and cell sciences, structural and medicinal chemistry, biopharm discovery and engineering, encoded libraries and chemical biology.
Prior to this appointment in 2018, Dave was head of the Respiratory Therapy Area at GSK where he led a group of over 200 scientists and clinicians who exploited scientific innovations with the potential to address the major unmet needs in diseases such as COPD, severe asthma, acute lung injury and idiopathic pulmonary fibrosis. Under Dave’s leadership, the team discovered, developed and launched a respiratory portfolio that included 8 first cycle approvals with successful products such as Relvar/Breo, Trelegy and Nucala.
Previously, Dave was head of Respiratory Drug Discovery and prior to that he led the Respiratory chemistry department where he managed the lead optimisation portfolio. He retains a keen interest in chemistry issues and was appointed GSK’s Chief Chemist in 2012. In addition, Dave is a member of a number of GSK’s senior decision-making boards. In November 2014, Dave was awarded an honorary Doctor of Science degree from the University of Strathclyde in recognition of his pioneering work in drug discovery.
Dave joined the company as a research chemist after completing his MA and BA at Oriel College, Oxford. During his career he has also worked on discovering antibiotics and cardiovascular medicines, as both a medicinal chemist and project leader.